Loading
Ever Supreme Bio Technology
Ever Supreme Bio Technology is a Taiwanese company developing immune cell and stem cell medicines. Its cancer medicine, CAR001, uses donor immune cells built to find tumours, and the FDA gave it orphan drug status for malignant glioma in 2026.
Also called: Ever Supreme Bio Technology Co., Ltd.Ever-SupremeEver Supreme Bio Technology, Co. Ltd.
Overview
Ever Supreme Bio Technology Co., Ltd., based in Taichung, was founded in 2016 by Dr Chang-Hai Tsai, according to the company, and works on immune cell, stem cell, nanoparticle and exosome technology platforms. Its lead cancer product, CAR001, is described by the company as an allogeneic CAR.BiTE gamma delta T-cell therapy that needs no leukapheresis, lymphodepletion or HLA matching. The company reports that the phase 1 part of its phase 1/2a trial (NCT06150885) treated 15 patients with relapsed or refractory colorectal cancer, glioblastoma, triple-negative breast cancer or non-small cell lung cancer, with one complete response in recurrent glioblastoma, and that the safety committee approved the phase 2a expansion in mid-2026. On 21 September 2026 the FDA granted orphan drug designation for malignant glioma to allogeneic gamma delta T cells modified by mRNA encoding a VHH-based CAR targeting HLA-G and a secretable BiTE targeting PD-L1.
Headquarters
Taichung, TW
Scorecard
All companies#545of 1706 companies, score 7
- phase 1/2 +1
- targets +2
- modalities +2
- 24-month regulatory events +2
0 approved, 0 in phase 3, 1 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.
Type
Website
Founded
2016
Products
1Phase 2Allogeneic CAR gamma delta T-cell therapy
CAR001 is an off-the-shelf immune cell therapy from Ever Supreme Bio Technology, made from donor gamma delta T cells. It is in an early trial in solid tumours, and the FDA has given it orphan drug status for malignant glioma.
Notes
- The FDA record describes the product without naming CAR001; the description matches the company's account of CAR001 and the HLA-G-CAR.BiTE cells in NCT06150885. The company's efficacy figures are its own. No HLA-G target record exists in the corpus. Read on 4 November 2026.
Connected
9Similar pages
- CompanyLuminary Therapeutics
Shares Gamma-delta T cell therapy, Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
- CompanyCARTx Therapeutics
- CompanyT-MAXIMUM Pharmaceutical
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy, Glioma & glioblastoma.
- CompanyEdiGene
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
- CompanyImugene
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
- CompanyTikva Allocell
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
- PersonStephen J. Forman
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
- CompanyAllotera Therapeutics (formerly Wugen)
Shares Allogeneic (off-the-shelf) cell therapy, CAR-T cell therapy.
cancers
fronts
technologies
targets
drugs
Phase 2Allogeneic CAR gamma delta T-cell therapy
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ever-supreme.com.tw · 3
US Food and Drug Administration · 1
A source that has moved or gone is reported by the weekly link check. /audit/